Meeting
2023 ASCO Annual Meeting
Association of circulating CD103+ T cells with major pathological response in a randomized phase 2 trial of neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small cell lung cancer.
Authors
Zachary Walsh
Columbia University Medical Center, New York, NY
Zachary Walsh , Johannes C Melms , Meri Rogava , Lindsay Caprio , Casey Ager , Amit Dipak Amin , Patricia Ho , Murtaza Malbari , Vivek Mittal , Timothy McGraw , Nasser K. Altorki , Benjamin Izar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8550)
DOI
10.1200/JCO.2023.41.16_suppl.8550
Abstract #
8550
Poster Bd #
177
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Stereotactic ablative radiotherapy with nivolumab for early-stage operable non-small cell lung cancer: A phase 2 study.
First Author: Gustavo Schvartsman
Poster
2018 ASCO Annual Meeting
Phase II randomized clinical trial comparing immunotherapy plus stereotactic ablative radiotherapy (I-SABR) versus SABR alone for stage I, selected stage IIa or isolated lung parenchymal recurrent non-small cell lung cancer: I-SABR.
First Author: Joe Y. Chang
Poster
2017 ASCO Annual Meeting
A phase II study of atezolizumab as neoadjuvant and adjuvant therapy in patients (pts) with resectable non-small cell lung cancer (NSCLC).
First Author: Dwight Hall Owen
Poster
2024 ASCO Annual Meeting
Association of napsin A-specific T cell clonotypes with durable clinical benefit to immunotherapy in patients with metastatic NSCLC.
First Author: Natalie J. Miller